January 2008
BioWorld Today;1/30/2008, Vol. 19 Issue 20, p2
This section offers pharmaceutical industry news briefs as of January 30, 2008. Cell Therapeutics Inc. has approved a proposal to increase its number of authorized shares from 110 million to 210 million. Compugen Ltd. has reported results of in vivo validation studies of CGEN-855A and CGEN-855B, anti-inflammatory and cardioprotective drug candidates. Cryo-Cell International Inc. formalized a research and development agreement with Saneron CCEL Therapeutics Inc.


Related Articles

  • OTHER NEWS TO NOTE.  // BioWorld Today;4/15/2008, Vol. 19 Issue 73, p2 

    This section offers news briefs on the pharmaceutical industry. Peter Mueller has been appointed by Amarillo Biosciences Inc. as chief operating officer and director of research. A deal has been entered by Antisoma PLC and Betagenon for Antisoma to license rights to develop Betagenon's AMPK...

  • OTHER NEWS TO NOTE.  // BioWorld Today;8/25/2008, Vol. 19 Issue 165, p2 

    This section offers news briefs on the pharmaceutical industry. Abbot approved a plan to streamline operations and reduce overall costs. Novato, California-based BioMarin Pharmaceutical Inc. rolled out its national PKU Demographics, Outcomes and Safety Registry, which is open to all patients...

  • Compugen Rockets on $540M Bayer Immunotherapy Alliance. Boggs, Jennifer // BioWorld International;8/7/2013, Vol. 18 Issue 32, p1 

    The article reports on the 44.5 percent increase in the share price of Compugen Ltd., a drug discovery company, following news of a possible 540-million-dollar deal with pharmaceutical company Bayer Healthcare to develop cancer immunotherapy drugs. Compugen began operating in the 1990s as a...

  • Cell Therapeutics closes public offering of common stock.  // PharmaWatch: Cancer;Sep2009, Vol. 8 Issue 9, p18 

    The article reports on the closure of public offering for the common stock with the amount of 33.73 million by biopharmaceutical company Cell Therapeutics Inc. in the U.S. It states that the company has already received about 40.3 million U.S. dollars in net proceeds from the offerings....

  • FINANCINGS ROUNDUP.  // BioWorld Today;6/13/2008, Vol. 19 Issue 115, p5 

    This section offers financial news briefs in the biopharmaceutical industry as of June 13, 2008. GenVec Inc. of Gaithersburg, Maryland raised $17 million from an offering of common shares. Active Biotech of Lund, Sweden raised $ 25.8 million from the issuance of new shares. Cell Therapeutics...

  • Medical Stock Spotlight.  // MondayMorning;9/17/2012, p1 

    The article offers news briefs related to the pharmaceutical industry highlighting the stock performance of several firms as of September 17, 2012. Neuralstem Inc. posted a 72 percent increase in stocks to $1.15 which has announced that its stem-cell therapy improved the condition of rats with...

  • Financings Roundup.  // BioWorld Today;7/1/2009, Vol. 20 Issue 125, p6 

    The article reports on the $3.6 million worth of fund received by Compugen Ltd. from the private sale of 1 million shares of Evogene Ltd. to a single purchaser. The proceeds is expected to be used by the company for general corporate purposes through mid-2010. The company still hold about 1.1...

  • Compugen Nets $19M for Diagnostic Discovery.  // Bioworld Week;1/4/2010, Vol. 18 Issue 1, p4 

    The article reports on the 20 million dollars profits that the Compugen Ltd. has raised after its major discovery-on-demand-deal with Pfizer Inc. It states that it achieved the amount through the sale of its 4.1 million ordinary shares at the rate of 4.91 per share. It also notes its negotiation...

  • Israeli Genomics Company Spin-Off to Focus on Small-Molecule Drugs. Terry, Mark // Drug Discovery & Development;Sep2004, Vol. 7 Issue 9, p20 

    The article reports on the announcement made by pharmaceutical company Compugen Ltd., to spun off its chemistry division into a subsidiary, Keddem Bioscience Ltd. Both Compugen and Keddem aim to increase the probability of success of drug discovery by incorporating ideas and methods from...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics